Clinical

Dataset Information

0

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach


ABSTRACT: This phase II trial is studying how well bortezomib with or without irinotecan works in treating patients with gastroesophageal junction or stomach cancer that can not be removed by surgery. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they stop growing or die. Combining bortezomib with irinotecan may kill more tumor cells.

DISEASE(S): Diffuse Adenocarcinoma Of The Stomach,Adenocarcinoma,Recurrent Gastric Cancer,Esophageal Neoplasms,Intestinal Adenocarcinoma Of The Stomach,Stage Iv Gastric Cancer,Adenocarcinoma Of The Gastroesophageal Junction,Stage Iiib Gastric Cancer,Stomach Neoplasms,Stage Iiic Gastric Cancer,Mixed Adenocarcinoma Of The Stomach

PROVIDER: 2009338 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2079139 | ecrin-mdr-crc
| 2099584 | ecrin-mdr-crc
| 2010924 | ecrin-mdr-crc
| 2010923 | ecrin-mdr-crc
| 2054608 | ecrin-mdr-crc
| 2051011 | ecrin-mdr-crc
| 2051191 | ecrin-mdr-crc
| 2011937 | ecrin-mdr-crc
| 2025494 | ecrin-mdr-crc
| 2012253 | ecrin-mdr-crc